Study of Nab-Paclitaxel in High Risk Early Breast Cancer

NCT01690702 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2886

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Epirubicin
DRUG: nab-Paclitaxel
DRUG: Cyclophosphamide
DRUG: Docetaxel

Sponsor

GBG Forschungs GmbH

Collaborators

[object Object]
[object Object]